Industry
Biotechnology
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 12:52 pm
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 12:17 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 9:21 pm
Portfolio Pulse from Benzinga Insights
May 07, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 4:00 pm
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 9:17 am
Portfolio Pulse from Avi Kapoor
March 26, 2024 | 11:37 am
Portfolio Pulse from Benzinga Newsdesk
March 20, 2024 | 2:57 pm
Portfolio Pulse from Benzinga Newsdesk
March 20, 2024 | 2:35 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.